RFA-AI-22-016 Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.